References
- Ticktin HE, Zimmerman HJ. Hepatic dysfunction and jaundice in patients receiving triacetyloleandomycin. N Engl J Med. 1962; 267: 96468.
- Zimmerman HJ. Intrahepatic Cholestasis. Arch Intern Med. 1979; 139: 1038–45.
- Perol R, Hincky J, Desnos M. Hepatites cholestatiques lors de la prise de troleandomycine chez deux femmes prenant des oestrogenes. Nouv Presse Med. 1978; 7: 4302.
- Miguet JP, Vuitton D, Allemand H et al. Une epidemie d’icteres due a l’association troIcandomycine-contraceptifs oraux. Gastroenterol Clin Biol. 1980; 4: 420–4.
- Klatskin G. Toxic and drug-induced hepatitis. In: SchifT L. ed. Diseases of the Liver. Phila delphia and Toronto: Lippincott Co 1975: 604–710.
- Goldberg DM, Spooner RJ, Ellis G, Ward AM. Biochemical features of intrahepatic cholestasis. Am J Clin Pathol. 1979; 71: 55763.
- Combes B, Shore GM, Cunningham FG et al. Serum lglutamyl-transpeptidase activity in viral hepatitis: suppression in pregnancy and by birth control pills. Gastroenterology. 1977; 72: 271–4.
- Dravet C, Mesdjihn E, Cenraud B, Rocer J. Interaction C arbamazenine-triacetyloleandomycine. Nouv Presse Med. 1977; 6: 467.
- Weinberger M, Hudgel D, Spector S, Chidsey C. Troleandomycin (TAO): an inhibitor of theophylline metabolism. J Allergy Clin Immunol. 1976; 57: 262.
- Pessayre D, Descatoire V, Konstantinovac Mitcheva M, et al. Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nmabsorbing complex with cytochrome P450. Biochem Pharmacol. 1981; 30: 553–8.
- Pessayre D, Konstantinova-Mitcheva M, Descatoire V et al. Hypoactivity of cytochrome P450 after triacetyloleandomycin administration. Biochem Pharmacol. 1981; 30: 559–64.
- Danau G, Descatoire V & Pessayre D. Selfinduction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P4J0. J Pharmacol Exp Ther. 1981; 218: 509–14.